|
- Shingles Vaccination in Rheumatology Patients
Vaccine eligibility can be checked in the Department of Health green book The NBT Rheumatology team may be recommending eligible individuals are vaccinated against shingles prior to starting potent immunosuppressants or biologic therapy, and will communicate this with you via the clinic letter
- Update: Shingrix vaccine eligible for over 50s - Rheumatology
Severely immunosuppressed patients over 50 will now be eligible for vaccination against Shingles with two doses of the Shingrix vaccine and prioritised via the national programme in line with BSR guidance
- Shingles vaccine - NHS
Find out about the shingles vaccine, including who it's for, how to get it and possible side effects
- Shingles immunisation programme: information for healthcare . . .
Based on the findings of the cost-effectiveness analysis, the JCVI recommended a universal routine herpes zoster (shingles) vaccination programme using a single dose of the live Zostavax
- Shingrix | Prescribing information | Shingles | CKS | NICE
Shingrix ® should be given by intramuscular injection, preferably in the deltoid region of the upper arm In the UK vaccination program, the second dose is given after an interval of 6-12 months in immunocompetent people, and after 8 weeks to 6 months in people who are immunosuppressed
- Vaccinations - Newcastle Hospitals NHS Foundation Trust
Vaccinations Vaccination is a safe and effective way of protecting yourself and others from potentially serious infection This is especially important if you take medications for your rheumatological disorder, as many of these drugs will suppress your immune system and increase your risk of infection
- General practice shingles vaccination programme technical guidance
In September 2021, Shingrix® was introduced in the NHS Shingles Vaccination Programme for individuals for whom the live Zostavax® was contraindicated
- Shingles vaccine offered to more immunosuppressed adults from September . . .
Eligible individuals will be offered two doses of the non-live shingles vaccine, Shingrix®, with the second dose administered 8 weeks to 6 months after the first, in line with the Summary of Product Characteristics (SmPC)
|
|
|